20１１ネン カラ ２０１３ネン ノ ヤマガタケン ニ オケル ミッツ ノ コトナル イデンシガタ ノ ハイエン マイコプラズマ ノ チイキテキ ヒロガリ ト マクロライド タイセイ カブ シュツゲン ノ タイミング ニ カンスル ケントウ by Suzuki Yu et al.
－19－
Regional spread of Mycoplasma pneumoniae
DOI  00.00000/00000000
Regional spread of three distinct genotypes of
Mycoplasma pneumoniae and different timing of
macrolide-resistant strain appearance among genotypes
between 2011 and 2013 in Yamagata, Japan
＊Department of Microbiology, Yamagata Prefectural Institute of Public Health
＊＊Department of Infectious Diseases, Yamagata University Faculty of Medicine
＊＊＊Yamanobe Pediatric Clinic, Yamanobe
＊＊＊＊Katsushima Pediatric Clinic, Yamagata
（Accepted September 24, 2019）
Yu Suzuki＊，＊＊， Junji Seto＊， Yoshitaka Shimotai＊＊， Tsutomu Itagaki＊＊＊，
Yuriko Katsushima＊＊＊＊， Fumio Katsushima＊＊＊＊， Tatsuya Ikeda＊， Katsumi Mizuta＊，
Seiji Hongo＊＊， Yoko Matsuzaki＊＊
Background: We previously revealed that several multiple-locus variable-number tandem-repeat 
analyses（MLVA）and P1 types of Mycoplasma pneumoniae（M. pneumoniae）cocirculated between 
2011 and 2013 in Yamagata, Japan. However, the regional spread of M. pneumoniae infection by 
genotype is not reported yet. It remains unclear whether there is a difference in the spread of 
macrolide-resistant M. pneumoniae among genotypes.
Methods: Genotypes were labeled according to 4-locus（Mpn 13, 14, 15, and 16）MLVA and P1 types. 
A total of 208 strains belonging to three major genotypes, i.e., type 4-5-7-2, 1; 4-5-7-3, 1; and 3-5-6-2, 2c, 
were analyzed by combining with the information of macrolide resistance-associated mutation and the 
patients’ information including residence.
Results and Discussion: The three genotypes were widely distributed over more than four cities 
and towns in Yamagata Prefecture, cocirculating between late 2011 and early 2013, and there was 
little difference in the duration of their epidemics. Timing of macrolide-resistant strain appearance 
during the epidemic period differed between type 4-5-7-2, 1 and type 4-5-7-3, 1, and it did not appear 
throughout type 3-5-6-2, 2c epidemic. These genotypic differences can account for the variation in the 
prevalence of macrolide resistance-associated mutations in each of the studied areas.
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Introduction
Mycoplasma pneumoniae（M. pneumoniae）is a 
common cause of upper and lower respiratory 
tract infections, particularly in children and young 
adults１），２）. This pathogen is responsible for up to 
20% of all cases of community-acquired pneumonia
（CAP）３）and 30% of pediatric cases of CAP４），５）. 
M. pneumoniae infections can be treated using 
macrolides（MLs）as first-line antibiotics６）－８）. 
However, since the year 2000, ML-resistant M. 
pneumoniae harboring a point mutation in its 
genome region coding the 23S rRNA domain V 
（ML resistance-associated mutation）has increased 
worldwide, contributing to increasing global public 
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health concerns６），９）.
Molecular typing of M. pneumoniae , including 
4-locus（Mpn13, 14, 15, and 16）multiple-locus 
variable-number tandem-repeat analysis（MLVA）
and P1 gene typing based on polymorphisms in 
the P1 gene encoding M. pneumoniae P1 adhesion 
protein, is an effective tool to understand the 
epidemiology of M. pneumoniae infection. Using these 
typing methods, we reported polyclonal spread of 
multiple genotypes of M. pneumoniae in schools10）. In 
addition, we revealed that several P1 and MLVA 
types of M. pneumoniae had cocirculated between 
2011 and 2013 in Yamagata Prefecture, Japan11），12）. 
However, the regional spread of M. pneumoniae 
infection by genotype is not reported yet. It remains 
unclear whether there is difference in the spread of 
ML-resistant M. pneumoniae among genotypes. In this 
study, we present detailed geographical and temporal 
distribution of M. pneumoniae isolates between 2011 
and 2013 in Yamagata Prefecture.
Methods
Study design:
Our previous study conducted between 2004 and 
2014 revealed that three major MLVA types of M. 
pneumoniae, including type 4-5-7-2, type 4-5-7-3, and 
type 3-5-6-2, cocirculated between 2011 and 2013 
in Yamagata, Japan11）. To elucidate the regional 
spread of M. pneumoniae infection by genotype, we 
performed a retrospective study of M. pneumoniae 
infection cases between 2011 and 2013 by combining 
the molecular typing results with the patients’ 
information. The profile of molecular typing and the 
ML susceptibility of the M. pneumoniae strains were 
obtained from our previous study11）. The genotypes 
of M. pneumoniae were defined using a combination 
of MLVA and P1 types and labeled in the order 
of MLVA type and P1 type. A total of 208 strains 
belonging to three major genotypes, i.e., type 4-5-
7-2, 1; 4-5-7-3, 1; and 3-5-6-2, 2c, were analyzed. The 
patients’ information including residence, specimen 
collection date, age, sex, and clinical diagnosis was 
collected from the medical records obtained from the 
Yamanobe Pediatric Clinic and Katsushima Pediatric 
Clinic in Yamagata, Japan. This study was approved 
by the Yamagata University Faculty of Medicine 
（H27-17）and Yamagata Prefectural Institute of 
Public Health（YPIPHEC 16-04）ethics committees.
Statistical analysis:
We examined the differences among the three 
genotypes. Kruskal–Wallis test was used for age, and 
Fisher’s exact test was used for sex, diagnosis, and 
prevalence of the ML resistance-associated mutation. 
When significant differences（P value < 0.05）
were detected among the three genotypes, multiple 
comparisons were performed. Wilcoxon rank sum 
test with the Benjamini–Hochberg procedure was 
used for age, and Fisher’s exact test with the 
Holm method was used for prevalence of the ML 
resistance-associated mutation. Statistical tests were 
performed using R version 3.4.1（The R Foundation, 
Vienna, Austria）.
Results and Discussion
We analyzed 208 strains belonging to three major 
genotypes, including 74 strains of type 4-5-7-2, 1, 74 
strains of type 4-5-7-3, 1, and 60 strains of type 3-5-
6-2, 2c. Table 1 shows the patients’ information 
and ML resistance-associated mutation prevalence 
among the three major genotypes. Statistical analysis 
revealed that patients infected with type 4-5-7-2, 1 
were significantly younger than the patients infected 
with type 3-5-6-2, 2c. In addition, the prevalence of 
ML resistance-associated mutations in type 4-5-7-2, 1 
（83.8%; 62/74）was significantly higher than that in 
type 4-5-7-3, 1（25.7%; 19/74）and type 3-5-6-2; 2c（0%; 
0/60）. However, there were no significant differences 
in clinical diagnosis, defined as the ratio of lower to 
upper respiratory tract infections, among the three 
genotypes, suggesting that there is no association 
between genotype and disease severity.
Figure 1 shows the geographical information 
of the three genotypes of M. pneumoniae, mapped 
according to districts（cities and towns）. Of the 208 
M. pneumoniae strains, 181（87%）were isolated in 
four of the studied districts: 72（34.6%）in Yamagata 
City, 48（23.1%）in Yamanobe Town, 42（20.2%）
in Sagae City, and 19（9.1%）in Nakayama Town. 
In these four districts, each of the three genotypes 
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was isolated. In the remaining six districts（Oe 
Town, Asahi Town, Kaminoyama City, Kahoku 
Town, Higashine City, and Tendo City）, one to two 
of the three genotypes were isolated. These findings 
suggest that the three genotypes of M. pneumoniae 
were widely distributed in the studied districts. 
Prevalence of ML resistance-associated mutation 
varied within each district, with 100%（2/2）in 
Kahoku Town; 75%（3/4）in Kaminoyama City; 
52.1%（25/48）in Yamanobe Town; 44.4%（32/72）
in Yamagata City; 40.5%（17/42）in Sagae City; 7.7%
（1/13）in Oe Town; 5.3%（1/19）in Nakayama 
Town; and 0% in Higashine City, Tendo City, and 
Asahi Town. The observed differences in the 
prevalence of this mutation according to different 
districts may reflect differences in its prevalence 
according to genotype（Table 1）.
Geographical and temporal information of the 
three genotypes of M. pneumoniae strains is shown 
in Figure 2（a）, where each year has been divided 
into three terms. A single genotype of type 4-5-7-
3, 1 was isolated during the first and second terms 
of 2011, whereas the three genotypes were isolated 
between the third term of 2011 and the first term of 
2013. Each of the three genotypes was isolated for 
seven terms（approximately a 28-month period）
in succession, which gradually spread to multiple 
surrounding districts. Monthly occurrence of each 
genotype with or without the ML resistance-
associated mutation is shown in Figure 2（b）. Type 
4-5-7-2, 1 was first isolated in October 2011, whereas 
the ML-resistant strain was prevalent from the 
initial period of its epidemic. Type 4-5-7-3, 1 was 
first isolated in January 2011; however, it did not 
possess the ML resistance-associated mutation until 
its emergence 11 months after the initial epidemic. 
Furthermore, type 3-5-6-2, 2c; first isolated in 
December 2011 and intermittently occurring until 
8 (1–45) 8 (3–63) 9 (1–56) 0.042‡
Sex Male 42 40 34 0.953
Female 32 34 26
Diagnosis 40 31 24 0.201
Upper respiratory
tract infection 34 43 36
Positive 62 19 0 <0.001§
Negative 12 55 60
Lower respiratory
tract infection
* Genotype was represented by the combination of VNTR numbers at 4 loci as
Mpn13–Mpn14–Mpn15–Mpn16 and P1 type.
† Kruskal–Wallis test was used for age and Fisher’s exact test was used for sex,
diagnosis, and prevalence of the ML resistance-associated mutation. When significant
differences (P value < 0.05) were detected among the three genotypes, multiple
comparisons were performed.
‡ Significant differences were obtained between type 4-5-7-2, 1 and 3-5-6-2, 2c (P  =
0.045) by multiple comparison (Wilcoxon rank sum test with the Benjamini–
Hochberg procedure).
§ Significant differences were obtained between type 4-5-7-2, 1 and 4-5-7-3, 1; 3-5-6-
2, 2c and between type 4-5-7-3, 1 and 3-5-6-2, 2c, respectively (P  < 0.001) by
multiple comparison (Fisher’s exact test with the Holm method).
4-5-7-2, 1
(n = 74)
4-5-7-3, 1
(n = 74)
3-5-6-2, 2c
(n = 60)
Genotype* of M. pneumoniae isolate
P  value†
Age, median (range)
Macrolide resistance-associated mutation
Table 1． Comparison of patient characteristics and macrolide 
 resistance-associated mutation prevalence among the 
 three major genotypes of Mycoplasma pneumoniae is 
 olated between 2011 and 2013 in Yamagata, Japan
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Figure２．Geographical and temporal information of the three genotypes 
（type 4-5-7-2, 1; type 4-5-7-3, 1; and type 3-5-6-2, 2c）of Mycoplasma pneumoniae 
isolated between 2011 and 2013 in Yamagata Prefecture, Japan.
（a）Distribution of M. pneumoniae strains by district, where each year was 
divided into three terms. Maps correspond to the gray area shown in Figure 1.
（b）Monthly occurrence of M. pneumoniae strains with or without the ML 
resistance-associated mutation.
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Figure１．Geographical information of the three genotypes（type 4-5-7-
2, 1; type 4-5-7-3, 1; and type 3-5-6-2, 2c）of Mycoplasma pneumoniae isolated 
between 2011 and 2013 in Yamagata Prefecture, Japan.
Gray area of the map displays the ten districts from where M. pneumoniae 
strains were derived. The proportion of genotypes and prevalence of the ML 
resistance-associated mutation by genotype are shown in the outer ring and 
inner circle, respectively. The numbers in the outer ring indicate the number 
of M. pneumoniae genotypes detected within each district.
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December 2013, did not possess the ML resistance-
associated mutation throughout the entirety of its 
epidemic period.
Prevalence of early emergence of the ML-resistant 
type 4-5-7-2, 1 M. pneumoniae may be due to the 
isolation of ML-resistant type 4-5-7-2, 1 strain in 
Yamagata Prefecture before 201111），12）. Type 4-5-7-
3, 1 strain, which had not been isolated before 2011 
in Yamagata Prefecture11），12）, was ML-susceptible 
during the initial period of its epidemic. Therefore, 
emergence of ML-resistant type 4-5-7-3, 1 strain may 
be associated with a selective pressure resulting 
from therapeutic ML use. Although type 3-5-6-
2, 2c strain, as well as type 4-5-7-3, 1 strain, had 
low prevalence in Yamagata Prefecture prior to 
201111），12）, ML-resistant type 3-5-6-2, 2c strain did not 
appear throughout its epidemic period. However, we 
previously reported that ML resistance-associated 
mutation emerged after ML treatment in a child 
infected with type 3-5-6-2, 2c M. pneumoniae as well 
as in children infected with type 4-5-7-3, 113）. Hence, 
our current findings suggest that type 3-5-6-2, 2c M. 
pneumoniae with a ML resistance-associated mutation 
has poor transmission ability compared with other 
genotypes. Further surveillance is needed to clarify 
the potential emergence of a ML-resistant type 3-5-6-
2, 2c strain in this area.
There are several limitations in this study. First, 
this study was conducted based on M. pneumoniae 
strains isolated from patients who visited only two 
pediatric clinics. The two clinics are located in 
Yamanobe Town and Yamagata City of Yamagata 
Prefecture; therefore, obtained findings may not 
reflect the situation of the whole prefecture. Second, 
we could not collect clinical information on anything 
except clinical diagnosis; therefore, we could not 
sufficiently compare severity among patients 
who were infected with different genotypes of M. 
pneumoniae. Our study was restricted to a local area 
and retrospectively performed; however, no similar 
studies that described regional difference in the 
prevalence of ML resistance-associated mutation by 
combining the molecular typing results is reported 
from other areas in Japan.
In summary, this study reveals that the three 
distinct genotypes of M. pneumoniae geographically 
and temporally cocirculate in Yamagata Prefecture, 
Japan and there is little difference in the duration of 
their epidemics. However, the timing of emergence 
of the ML-resistant strain differs for each genotype. 
These genotypic distinctions may account for 
the observed differences in the prevalence of ML 
resistance-associated mutation in each of the studied 
areas. Provision of early information about the 
genotype of  circulating in each region will help 
clinicians choose specific antibiotics against  infection. 
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